Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Medtronic
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,569,443

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,569,443 protect, and when does it expire?

Patent 6,569,443 protects AZASITE and is included in one NDA.

This patent has thirty patent family members in sixteen countries.

Summary for Patent: 6,569,443
Title: Topical treatment or prevention of ocular infections
Abstract:The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.
Inventor(s): Dawson; Chandler R. (Mill Valley, CA), Bowman; Lyle M. (Pleasanton, CA)
Assignee: Insite Vision, Inc. (Alameda, CA)
Application Number:09/767,943
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,569,443
Patent Claim Types:
see list of patent claims
Use; Composition; Process; Compound; Formulation;

Drugs Protected by US Patent 6,569,443

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Oak Pharms Inc AZASITE azithromycin SOLUTION/DROPS;OPHTHALMIC 050810-001 Apr 27, 2007 RX Yes Yes   Start Trial   Start Trial Y METHOD OF COMBATING BACTERIA IN A PATIENT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,569,443

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 296093   Start Trial
Australia 2002322002   Start Trial
Australia 3920300   Start Trial
Australia 772228   Start Trial
Canada 2368637   Start Trial
Canada 2445408   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
McKinsey
Harvard Business School
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.